Regulatory approval
Published by the Health Service Executive. Approved
Treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.
This is written in the approval document.
Reimbursement
CDS
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HSE (1) | TP53 Somatic variants | Chronic Lymphocytic Leukemia | Venetoclax | |
| HSE (1) | TP53 deletion | Chronic Lymphocytic Leukemia | Venetoclax | |
| HSE (1) | 17p deletion | Chronic Lymphocytic Leukemia | Venetoclax |
Contributions
| Date | Contributor | Description |
|---|---|---|
| 2024-01-16 | Van Allen lab | Adding HSE approvals for reimbursement to database |
| 2018-12-01 | Health Service Executive | Indication approved for reimbursement. |